These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 23464522)
1. Tubulin: an example of targeted chemotherapy. Seligmann J; Twelves C Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522 [TBL] [Abstract][Full Text] [Related]
2. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Yardley DA Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502 [TBL] [Abstract][Full Text] [Related]
3. Microtubule active agents: beyond the taxane frontier. Morris PG; Fornier MN Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832 [TBL] [Abstract][Full Text] [Related]
4. Microtubules: a dynamic target in cancer therapy. Pasquier E; Kavallaris M IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008 [TBL] [Abstract][Full Text] [Related]
5. βIII-Tubulin: biomarker of taxane resistance or drug target? Karki R; Mariani M; Andreoli M; He S; Scambia G; Shahabi S; Ferlini C Expert Opin Ther Targets; 2013 Apr; 17(4):461-72. PubMed ID: 23379899 [TBL] [Abstract][Full Text] [Related]
7. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795 [TBL] [Abstract][Full Text] [Related]
8. Marine Derived Anticancer Drugs Targeting Microtubule. De O; Chatterji BP Recent Pat Anticancer Drug Discov; 2017; 12(2):102-127. PubMed ID: 28067173 [TBL] [Abstract][Full Text] [Related]
9. Tubulin and microtubules as targets for anticancer drugs. Hadfield JA; Ducki S; Hirst N; McGown AT Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726 [TBL] [Abstract][Full Text] [Related]
10. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Perez EA Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735 [TBL] [Abstract][Full Text] [Related]
11. Tubulin-targeted agents including docetaxel and cabazitaxel. Cheetham P; Petrylak DP Cancer J; 2013; 19(1):59-65. PubMed ID: 23337758 [TBL] [Abstract][Full Text] [Related]
12. The epothilones: how pharmacology relates to clinical utility. Michaud LB Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389 [TBL] [Abstract][Full Text] [Related]
13. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Vahdat L Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531 [TBL] [Abstract][Full Text] [Related]
19. Current perspectives of epothilones in breast cancer. Cardoso F; de Azambuja E; Lago LD Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426 [TBL] [Abstract][Full Text] [Related]
20. Cabazitaxel: a novel drug for hormone-refractory prostate cancer. Malhotra M; Dhingra R; Sharma T; Deep A; Narasimhan B; Phogat P; Sharma PC Mini Rev Med Chem; 2013 May; 13(6):915-20. PubMed ID: 22950608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]